Clinical Trial Update: A Phase 3 Study to Evaluate the Safety and Tolerability of L606 in Subjects With PAH or PH-ILD [Phase 3]

View source ↗

Summary

This clinical trial update notes a Phase 3 study evaluating the safety and tolerability of L606 in patients with pulmonary arterial hypertension or pulmonary hy…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Arterial Hypertension
• Pulmonary Hypertension Due to Lung Diseases

Drugs mentioned

• L606

Snippet

Sponsor: Liquidia Technologies, Inc. | Conditions: Pulmonary Arterial Hypertension, Pulmonary Hypertension Due to Lung Diseases | Phase 3 | Status: ACTIVE_NOT_RECRUITING